Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 20/20 | 1.00 |
| ▸ | DDX5 | P17844 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689186 | 0.91 | TOP1 (1.00) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL27477075 | 0.91 | TOP1 (0.84) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL28177312 | 0.91 | TOP1 (1.00) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL24684716 | 0.91 | TOP1 (1.00) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL27515143 | 0.90 | TOP1 (0.81) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL23813726 | 0.90 | TOP1 (0.81) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL27479909 | 0.88 | TOP1 (0.79) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL27477499 | 0.87 | TOP1 (0.77) | TOP1DDX5MEN1ALDH1A1GLA | |
| SCHEMBL18350047 | 0.87 | TOP1 (0.77) | TOP1DDX5ALDH1A1GLASMN1; SMN2 | |
| SCHEMBL27463599 | 0.87 | TOP1 (0.78) | TOP1DDX5MEN1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| EP-4720127-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250298025-A1 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-09-25 | — | — | US | disclosed |
| EP-4605429-A1 | ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-120091834-A | Antibody-drug conjugate, preparation method and application thereof | 普众发现医药科技(上海)有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120077074-A | Antibody-drug conjugate, preparation method thereof and application thereof in resisting tumor | 普众发现医药科技(上海)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240424007-A1 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPID VESICLES | Jazz Pharmaceuticals Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| WO-2024240227-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2024-11-28 | — | — | WO | disclosed |
| EP-4444360-A1 | ANTI-CDH6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118302199-A | Anti-CDH 6 antibodies and antibody-drug conjugates thereof | 普众发现医药科技(上海)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3922241-B1 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | CELATOR PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116916968-A | Oligonucleotide-based therapeutics and uses thereof | 托德·斯皮尔 | 2023-10-20 | — | — | CN | disclosed |
| EP-4237087-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | Speer, Tod (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023102875-A1 | ANTI-CDH6 ANTIBODY DRUG CONJUGATE | MULTITUDE THERAPEUTICS INC. (CN) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104188-A1 | ANTI-CDH6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022094609-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | SPEER TOD (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114099437-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114073678-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20160375042-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | ZHOU WENQIANG (CN) | 2016-12-29 | — | — | US | disclosed |
| EP-3100734-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | Zhou, Wenqiang (CN) | 2016-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375042-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | SLC11A2, MCL1, ABCC1 | TOP1 48/4885DDX5 2869/4885MEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.